CN115003295B - 具有雌激素受体降解活性的新型色满衍生物及其用途 - Google Patents

具有雌激素受体降解活性的新型色满衍生物及其用途 Download PDF

Info

Publication number
CN115003295B
CN115003295B CN202080092528.XA CN202080092528A CN115003295B CN 115003295 B CN115003295 B CN 115003295B CN 202080092528 A CN202080092528 A CN 202080092528A CN 115003295 B CN115003295 B CN 115003295B
Authority
CN
China
Prior art keywords
cancer
compound
phenyl
piperidin
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080092528.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115003295A (zh
Inventor
范捷
Y.钱
W.何
刘坷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accutar Biotechnology Inc
Original Assignee
Accutar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accutar Biotechnology Inc filed Critical Accutar Biotechnology Inc
Priority to CN202510495956.1A priority Critical patent/CN120665056A/zh
Publication of CN115003295A publication Critical patent/CN115003295A/zh
Application granted granted Critical
Publication of CN115003295B publication Critical patent/CN115003295B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080092528.XA 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途 Active CN115003295B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510495956.1A CN120665056A (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947213P 2019-12-12 2019-12-12
US62/947,213 2019-12-12
PCT/US2020/027895 WO2021118629A1 (en) 2019-12-12 2020-04-13 Novel chroman derivatives having estrogen receptor degradation activity and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510495956.1A Division CN120665056A (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途

Publications (2)

Publication Number Publication Date
CN115003295A CN115003295A (zh) 2022-09-02
CN115003295B true CN115003295B (zh) 2025-05-06

Family

ID=70289288

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080092528.XA Active CN115003295B (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途
CN202510495956.1A Pending CN120665056A (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510495956.1A Pending CN120665056A (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途

Country Status (11)

Country Link
US (2) US10800770B1 (https=)
EP (2) EP3835298B1 (https=)
JP (2) JP7662639B2 (https=)
KR (1) KR102942706B1 (https=)
CN (2) CN115003295B (https=)
CA (1) CA3164202A1 (https=)
DK (1) DK3835298T3 (https=)
ES (1) ES2986594T3 (https=)
FI (1) FI3835298T3 (https=)
MX (1) MX2022007155A (https=)
WO (1) WO2021118629A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
CN111606883B (zh) 2019-02-25 2023-05-09 上海科技大学 基于戊二酰亚胺骨架的含硫化合物及其应用
WO2021023233A1 (zh) 2019-08-05 2021-02-11 上海科技大学 Egfr蛋白降解剂及其抗肿瘤应用
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
EP3835298B1 (en) * 2019-12-12 2024-06-26 Accutar Biotechnology Inc. Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
JP2023508357A (ja) * 2019-12-23 2023-03-02 アキュター バイオテクノロジー インコーポレイテッド エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ
AU2021226514B2 (en) * 2020-02-25 2023-10-19 Shanghaitech University Glutarimide skeleton-based compounds and application thereof
WO2022056368A1 (en) 2020-09-14 2022-03-17 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
WO2022166879A1 (zh) * 2021-02-04 2022-08-11 正大天晴药业集团股份有限公司 苯并七元环类双功能化合物及其应用
WO2022187588A1 (en) * 2021-03-04 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of estrogen receptor with cereblon ligands
CA3211378A1 (en) 2021-03-29 2022-10-06 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
CA3227425A1 (en) 2021-07-26 2023-02-02 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
CA3235512A1 (en) * 2021-10-22 2023-04-27 Xiaobao Yang Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications
CN113816927B (zh) * 2021-11-23 2022-02-25 苏州国匡医药科技有限公司 一种arv-471中间体的制备方法
CN117229286A (zh) 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
US20260000676A1 (en) * 2022-07-12 2026-01-01 The Regents Of The University Of Michigan Chroman derivatives as estrogen receptor degraders
CN116751186B (zh) * 2022-12-23 2024-10-18 南京知和医药科技有限公司 一种雌激素受体调节剂的制备及其用途
TWI882643B (zh) * 2023-01-16 2025-05-01 大陸商南京明德新藥研發有限公司 取代的苯並七元環化合物及其應用
CN119258223A (zh) * 2023-07-06 2025-01-07 海创药业股份有限公司 一种降解雌激素受体的联合用药物及其用途
US20250381179A1 (en) 2024-05-22 2025-12-18 Accutar Biotechnology Inc. Chroman-based compounds for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495618A (zh) * 2016-07-12 2018-09-04 冰洲石生物科技公司 新的化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021710A1 (en) * 1996-10-28 2001-09-13 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO1998018778A1 (en) * 1996-10-28 1998-05-07 Novo Nordisk A/S Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
JP2001502711A (ja) * 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は治療において有用な新規のシス―３、４―クロマン誘導体
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
JP2005524630A (ja) * 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
WO2003063659A1 (de) 2002-02-01 2003-08-07 Danny Bellens Ablageständer
CA2512000C (en) * 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
PL3202460T3 (pl) * 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
US10053451B2 (en) * 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
BR112019011200B1 (pt) * 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
EP3835298B1 (en) * 2019-12-12 2024-06-26 Accutar Biotechnology Inc. Novel chroman derivatives having estrogen receptor degradation activity and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495618A (zh) * 2016-07-12 2018-09-04 冰洲石生物科技公司 新的化合物及其用途

Also Published As

Publication number Publication date
CN120665056A (zh) 2025-09-19
WO2021118629A1 (en) 2021-06-17
KR102942706B1 (ko) 2026-03-20
MX2022007155A (es) 2022-10-07
ES2986594T3 (es) 2024-11-12
DK3835298T3 (da) 2024-07-29
CN115003295A (zh) 2022-09-02
FI3835298T3 (fi) 2024-07-29
JP2025081364A (ja) 2025-05-27
CA3164202A1 (en) 2021-06-17
EP4420728A3 (en) 2024-10-30
US10800770B1 (en) 2020-10-13
EP3835298A1 (en) 2021-06-16
JP2023506155A (ja) 2023-02-15
KR20220118460A (ko) 2022-08-25
EP3835298B1 (en) 2024-06-26
JP7662639B2 (ja) 2025-04-15
US20210221802A1 (en) 2021-07-22
EP4420728A2 (en) 2024-08-28
US11261178B2 (en) 2022-03-01

Similar Documents

Publication Publication Date Title
CN115003295B (zh) 具有雌激素受体降解活性的新型色满衍生物及其用途
CN113164409B (zh) 具有雌激素受体α降解活性的化合物及其用途
CN111225896B (zh) 免疫调节剂化合物
CN113329999B (zh) 具有雄激素受体降解活性的新型取代的喹啉-8-甲腈衍生物及其用途
WO2020114482A1 (zh) 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
WO2021061644A1 (en) Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
RU2727705C1 (ru) Производное бензопиперидина, способ его получения и его медицинское применение
WO2019085933A1 (zh) 作为Wee1抑制剂的大环类化合物及其应用
EP3312184A1 (en) Piperidine derivative and preparation method and pharmaceutical use thereof
JP2022549222A (ja) アンドロゲン受容体分解活性を有する新規尿素およびその使用
RU2722441C2 (ru) Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена
US20220064176A1 (en) Isocarbostyril alkaloids and functionalization thereof
CN116438177B (zh) 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
HK40080061A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
CA2985021A1 (en) Selective modulators of the activity of the gpr55 receptor: chromenopyrazole derivatives
HK40080061B (zh) 具有雌激素受体降解活性的新型色满衍生物及其用途
HK40115205A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
JP2009517357A (ja) イソキノリンおよびベンゾ［ｈ］イソキノリン誘導体、調製およびヒスタミンｈ３受容体のアンタゴニストとしてのこの治療上の使用
HK40058838A (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof
KR20260040160A (ko) Cyp11a1 억제제로서의 신규 화합물 및 그 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080061

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant